Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
F-Star Therapeutics
F-Star Therapeutics is a biopharmaceutical company that develops novel bispecific antibody products to improve the current standard of care.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cend Therapeutics Inc.
Cend Therapeutics Inc. develops cancer therapies that overcome drug delivery barriers to solid tumors.
Sector
Subsector
Keywords
Location
total rounds
total raised
Innate Pharma
Innate Pharma S.A. is a global biotech company that develops therapeutic antibodies to fight cancer by harnessing the immune system.
Sector
Subsector
Keywords
Location
total rounds
total raised
Peloton Therapeutics
Peloton Therapeutics is a biopharmaceutical company developing cancer drugs.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Celldex Therapeutics
announced date
price
Financials
Funding Rounds6
Number of Funding Rounds
Money Raised
Their latest funding was raised on 19.03.2014. Their latest investor Purdue Pharma. Their latest round Series D
OUP (Osage University Partners)
Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups commercializing university research.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Purdue Pharma
Purdue Pharma is a private company that develops, manufactures and markets medications and consumer health products.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
HBM Healthcare Investments AG
HBM Healthcare Investments finances companies in the medical and biotech sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Deerfield
Deerfield is an investment management firm that specializes in healthcare investments, including information, investment, and philanthropy.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Fidelity
Fidelity is a privately-owned investment manager that offers a wide range of financial services.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
KLP Enterprises
In Q2 2022, the company did not have any founders.
Sector
Subsector
Location
count Of Investments
count Of Exists
HBM Healthcare Investments AG
HBM Healthcare Investments finances companies in the medical and biotech sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors9
Number of lead investors
Number of investors
Purdue Pharma
Purdue Pharma is a private company that develops, manufactures and markets medications and consumer health products.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Elm Street Ventures
ESVC creates life sciences companies from Yale University's intellectual property and other regional research institutions.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
HBM Healthcare Investments AG
HBM Healthcare Investments finances companies in the medical and biotech sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders3
Arthur Altschul Jr.
Arthur G. Altschul, Jr., is the co-Founder of Kolltan and Chairman of Kolltan's Board of Directors. Mr. Altschul has worked in money management, investment banking and as a member of senior management of a publicly-traded health care concern. He is a founder of Diaz & Altschul Capital Management, LLC, a private investment advisory firm. Between 1985 and 1991, Mr. Altschul worked, variously, at Goldman, Sachs & Co., The Maximus Fund, LP and Morgan Stanley & Co. From its founding in 1992 through 1996, Mr. Altschul worked at SUGEN, Inc., a biopharmaceutical company focused on cancer drug development, which is now owned by Pfizer, Inc. Mr. Altschul serves on the board of directors of General American Investors, Inc. (NYSE: GAM), a publicly-traded closed-end investment company with over $1 billion in gross assets and Medicis Pharmaceutical Corporation (NYSE: MRX), the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. Mr. Altschul is a director of The Overbrook Foundation, a trustee of The Neurosciences Research Foundation, and a director of the Child Mind Institute. Mr. Altschul received his B.Sc. in Computer Science from Columbia University.
current job
organization founded
Arthur Altschul Jr.
Joseph Schlessinger
Joseph Schlessinger is the co-Founder of Kolltan, a member of Kolltan's Board of Directors and Chairman of Kolltan's Scientific Advisory Board. Schlessinger is the Chairman of the Department of Pharmacology and the William Prusoff Professor at Yale School of Medicine and the Director of the Cancer Biology Institute of Yale University. From 1990 to 2001, he was Chairman of the Department of Pharmacology and the Helen and Milton A. Kimmelman Professor at New York University Langone Medical Center. He was also the director of the Skirball Institute of NYU from 1998 until 2001. Before co-founding Kolltan, he co-founded SUGEN, Inc. in 1991 and in 2001 he co-founded Plexxikon. He was also the chairman of Plexxikon's Board of Directors and a member of Plexxikon's Scientific Advisory Board from 2001 until 2011. From 1980 to 1991, Schlessinger was the Ruth and Leonard Simon Professor in Cancer Research in the Department of Chemical Immunology at the Weizmann Institute of Science, Rehovot, Israel. Schlessinger was research director at Rorer Biotechnology, Inc. in Pennsylvania from 1988 to 1990. He has also held positions at Meloy Laboratories, Inc. in Rockville, Maryland from 1985 to 1988. Schlessinger has authored or co-authored more than 475 scientific articles and papers focusing on signal transduction, growth control mechanisms, receptor structure functions and the biophysics of proteins. He is a member of the National Academy of Science, a fellow of the American Academy of Arts and Sciences, a member of the Institute of Medicine at the National Academies, a member of the European Academy of Science, and a foreign member of the Russian Academy of Sciences. He is on the editorial boards of Cell, Molecular Cell, and the Journal of Cellular Biology as well as many other journals. Schlessinger's academic honors include the Drew Ciba Prize, the Antoine Lacassagne Prize, the Dan David Prize, the Distinguished Service Award of Miami Biotechnology, an Honorary Membership of the Japanese Biochemical Society, Honorary Doctor of Philosophy from the University of Haifa, the Medal of Danica Hrvatska Order from the Republic of Croatia and the Penzcoller-AACR International Award for Cancer among many others. He presented the E.J. Cohn Lecture at Harvard Medical School, the Edmond Fischer Lecture at the University of Geneva, the Lamport Lecture at the University of Seattle, the Harvey Lecture at Rockefeller University, the Opening Keynote Lecture at the American Society for Biochemistry and Molecular Biology annual meeting, the NIH Director Lecture, the Distinguished Lecture on Molecular Targets for Cancer Prevention at the AACR in Baltimore, Maryland, the NIH-WALS Lecture in Bethesda, Maryland and the Twenty-fourth Medical Scientist Lecture Series at UC Irvine, the Ef Racker Lecture in Biology and Medicine, at Cornell university as well as numerous others. Schlessinger received his B.Sc., Magna Cum Laude, in chemistry and physics and his M.Sc., Magna Cum Laude, in chemistry from the Hebrew University in Jerusalem, Israel. He received his Ph.D. from the Department of Chemical Physics at the Weizmann Institute in Rehovot, Israel in the field of biophysics.
current job
organization founded
Joseph Schlessinger
Lawrence Fritz
Lawrence C. Fritz is a successful biotechnology entrepreneur with over 25 years of experience in the industry. Prior to joining Auspex he was Founder, President and CEO of Covella Pharmaceuticals, a company focused on inflammatory diseases. Covella was acquired in 2010 by Santarus, Inc. Prior to Covella, he founded Conforma Therapeutics and served as its President and CEO from inception through its acquisition by Biogen Idec in 2006. Conforma focused on the discovery and development of novel small-molecule drugs for cancer therapy. Fritz was also a founder and Director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma; Cabrellis was subsequently acquired by Pharmion Corporation. Prior to Conforma, Fritz co-founded both Athena Neurosciences, now wholly-owned by Elan Corporation, and Idun Pharmaceuticals, subsequently acquired by Pfizer. In addition to his work in private biotechnology companies, Fritz served as President and CEO of Anadys Pharmaceuticals, a NASDAQ-listed public company developing drugs for viral diseases and oncology. Fritz is also an Entrepreneur-in-Residence with the venture capital firm Thomas, McNerney & Partners. He holds an A.B. in Biochemical Sciences from Harvard, an M.Sc. in Physiology from University College London, and a Ph.D. in Biophysics from The Rockefeller University.
current job
organization founded
Lawrence Fritz
Employee Profiles28
Keith Darragh
Vice President of Finance & Administration and Treasurer
Carolyn F. Sidor
Senior Vice President of Clinical and Regulatory Affairs & Chief Medical Officer
Ed Natoli
Scientist, department of bioprocess development
Carmela Senese
Executive assistant to president and ceo, svpchief financial and business officer